OA10355A - 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity - Google Patents

1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity Download PDF

Info

Publication number
OA10355A
OA10355A OA60722A OA60722A OA10355A OA 10355 A OA10355 A OA 10355A OA 60722 A OA60722 A OA 60722A OA 60722 A OA60722 A OA 60722A OA 10355 A OA10355 A OA 10355A
Authority
OA
OAPI
Prior art keywords
phenyl
formula
group
4alkyl
compound
Prior art date
Application number
OA60722A
Other languages
English (en)
Inventor
Elizabeth Ellen Sugg
Christopher Joseph Aquino
Jerzy Ryszard Szewczyk
Harry Finch
Robin Arthur Ellis Carr
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of OA10355A publication Critical patent/OA10355A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
OA60722A 1993-04-15 1995-10-12 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity OA10355A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (1)

Publication Number Publication Date
OA10355A true OA10355A (en) 2001-10-19

Family

ID=10733915

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60722A OA10355A (en) 1993-04-15 1995-10-12 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity

Country Status (34)

Country Link
US (2) US5646140A (es)
EP (1) EP0694039B1 (es)
JP (1) JP3406317B2 (es)
KR (1) KR100364948B1 (es)
CN (1) CN1058487C (es)
AP (2) AP512A (es)
AT (1) ATE198894T1 (es)
AU (1) AU681139B2 (es)
CA (1) CA2158973C (es)
CZ (1) CZ286695B6 (es)
DE (1) DE69426624T2 (es)
DK (1) DK0694039T3 (es)
EC (1) ECSP941066A (es)
ES (1) ES2154674T3 (es)
FI (1) FI954853A0 (es)
GB (1) GB9307833D0 (es)
GR (1) GR3035641T3 (es)
HK (1) HK1003943A1 (es)
HU (1) HU223467B1 (es)
IL (2) IL109315A0 (es)
IS (2) IS4147A (es)
MY (2) MY131569A (es)
NO (1) NO311133B1 (es)
NZ (1) NZ265272A (es)
OA (1) OA10355A (es)
PE (2) PE50594A1 (es)
PH (1) PH30897A (es)
PL (1) PL178790B1 (es)
PT (1) PT694039E (es)
RU (1) RU2135486C1 (es)
SK (1) SK281211B6 (es)
TW (1) TW487703B (es)
WO (1) WO1994024149A1 (es)
ZA (2) ZA942571B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430068T2 (de) * 1993-12-28 2002-08-14 SHIONOGI & CO., LTD. Benzodiazepinderivate
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
CA2186900A1 (en) * 1994-04-14 1995-10-26 Christopher Joseph Aquino Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
EP0755394A1 (en) * 1994-04-15 1997-01-29 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
PT945445E (pt) * 1996-12-10 2004-01-30 Zeria Pharm Co Ltd Derivados de 1,5-benzodiazepina
CA2283564C (en) 1997-04-15 2007-07-10 Csir Pharmaceutical compositions having appetite suppressant activity
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
EA010888B1 (ru) * 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
EP2054390B1 (en) * 2006-08-25 2012-04-11 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
LT3071203T (lt) 2013-11-18 2021-05-25 Forma Therapeutics, Inc. Tetrahidrochinolino kompozicijos kaip bet bromodomeno inhibitoriai
MX2018000916A (es) 2015-07-22 2018-09-05 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de rsv.
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
ES2912295T3 (es) 2016-12-09 2022-05-25 Denali Therapeutics Inc Compuestos útiles como inhibidores de RIPK1
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
CA2186900A1 (en) * 1994-04-14 1995-10-26 Christopher Joseph Aquino Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines

Also Published As

Publication number Publication date
SK125395A3 (en) 1996-06-05
AU6567694A (en) 1994-11-08
IL109316A (en) 1999-03-12
NO954090D0 (no) 1995-10-13
CN1120843A (zh) 1996-04-17
US5646140A (en) 1997-07-08
FI954853A (fi) 1995-10-12
US5585376A (en) 1996-12-17
RU2135486C1 (ru) 1999-08-27
DE69426624T2 (de) 2001-06-21
CA2158973C (en) 2006-06-06
GR3035641T3 (en) 2001-06-29
HU9502978D0 (en) 1995-12-28
DK0694039T3 (da) 2001-05-21
EP0694039B1 (en) 2001-01-24
CZ286695B6 (en) 2000-06-14
NZ265272A (en) 1997-07-27
ZA942571B (en) 1994-11-11
IL109316A0 (en) 1994-07-31
FI954853A0 (fi) 1995-10-12
KR100364948B1 (ko) 2003-03-29
AP462A (en) 1996-02-19
PE50994A1 (es) 1995-01-06
AP9400635A0 (en) 1994-04-30
ZA942570B (en) 1994-11-11
PH30897A (en) 1997-12-23
NO311133B1 (no) 2001-10-15
CZ267595A3 (en) 1996-04-17
HK1003943A1 (en) 1998-11-13
CA2158973A1 (en) 1994-10-27
EP0694039A1 (en) 1996-01-31
HU223467B1 (hu) 2004-07-28
ES2154674T3 (es) 2001-04-16
PL178790B1 (pl) 2000-06-30
HUT74102A (en) 1996-11-28
AP512A (en) 1996-07-29
ATE198894T1 (de) 2001-02-15
AP9400634A0 (en) 1994-04-30
JP3406317B2 (ja) 2003-05-12
AU681139B2 (en) 1997-08-21
CN1058487C (zh) 2000-11-15
TW487703B (en) 2002-05-21
PL311084A1 (en) 1996-02-05
PE50594A1 (es) 1995-01-06
GB9307833D0 (en) 1993-06-02
IS4147A (is) 1994-10-16
IS4148A (is) 1994-10-16
PT694039E (pt) 2001-06-29
NO954090L (no) 1995-12-13
IL109315A0 (en) 1994-07-31
DE69426624D1 (de) 2001-03-01
WO1994024149A1 (en) 1994-10-27
ECSP941066A (es) 1994-11-16
JPH08508744A (ja) 1996-09-17
MY131569A (en) 2007-08-30
SK281211B6 (sk) 2001-01-18
MY112237A (en) 2001-05-31

Similar Documents

Publication Publication Date Title
OA10355A (en) 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity
AU679085B2 (en) Benzodiazepine analogs
US5795887A (en) Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
US5739129A (en) CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
EP0756602B1 (en) Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5686449A (en) 1,5-benzodiazepines useful as gastrinor CCK-antagonists
US5910495A (en) Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
OA10236A (en) 1,5 Benzodiazepine derivatives having cck and/or gastrin antagonistic activity
US5739162A (en) Carbamoylmethylurea derivatives